The FDA has approved cemiplimab-rwlc, marketed as Libtayo, as the first immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma with a high risk of recurrence after surgery and radiation.
Tarrytown, N.Y.-based Regeneron Pharmaceuticals received approval Oct. 8 following a priority review. The decision was based on results from a phase 3 randomized trial, which showed Libtayo reduced the risk of disease recurrence or death by 68% compared to placebo.
This approval adds to Libtayo’s growing list of indications, which include advanced forms of skin and lung cancers.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
